Press releases
Year-end report 1 July 2025 – 30 June 2026
31 August, 2026Fourth quarter summary, April – June 2026 Net sales amounted to MSEK 0.0 (0.0) Operating profit amounted to MSEK -1.9 (-1.6) Earnings per share* SEK -0.10 (-0.08) Clinical highlights […]
DexTech Medical’s myeloma study fully recruited, preliminary results very positive
4 June, 2026The study was conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment has lasted for a total of 14 weeks with 2 doses per month. Three dose […]
Interim Report 1 July 2025 – 31 March 2026
5 May, 2026Summary of the third quarter (2026-01-01 – 2026-03-31) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.7 million (-1.3) Earnings per share* SEK -0.09 (-0.07) […]
Half-year report July 1 – December 31, 2025
25 February, 2026Summary of the second quarter (2025-10-01 – 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit/loss amounted to MSEK -1.7 (-1.1) Earnings per share* SEK -0.09 (-0.05) More than […]
DexTech Medical’s myeloma study, completed at the end of February 2026, concludes with continued strong results
27 January, 2026The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose […]
DexTech Medical’s Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3
3 December, 2025The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose […]
Bulletin from the Annual General Meeting
4 November, 2025Today, November 4, 2025, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and […]
Interim report July 1- September 30, 2025
3 November, 2025Summary of the first quarter (2025-07-01 – 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit/loss amounted to MSEK -1.3 (-1.3) Earnings per share* SEK -0.07 (-0.06) Cash and […]
DexTech Medical’s Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3
16 October, 2025The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose […]
DexTech: Invitation to open Annual General Meeting and notice
3 October, 2025On Tuesday, November 4, 2025, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]